JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB256984

Human MAP3K7 (TAK1) knockout HEK-293T cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

MAP3K7 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 2 bp insertion in exon 6.
2 Images
Western blot - Human MAP3K7 (TAK1) knockout HEK-293T cell lysate (AB256984)
  • WB

Lab

Western blot - Human MAP3K7 (TAK1) knockout HEK-293T cell lysate (AB256984)

Lane 1 : Wild-type HEK-293T cell lysate (20µg)

Lane 2 : MAP3K7 knockout HEK-293T cell lysate (20µg)

Lanes 1- 2 : Merged signal (red and green). Green - ab109526 observed at 72 kDa. Red - loading control ab8245 observed at 37 kDa.

ab109526 Anti-TAK1 antibody [EPR5984] was shown to specifically react with TAK1 in wild-type HEK-293T cells in western blot. Loss of signal was observed when knockout cell line ab266555 (knockout cell lysate ab256984) was used. Wild-type and TAK1 knockout samples were subjected to SDS-PAGE. Membrane was blocked for 1 hour at room temperature in 0.1% TBST with 3% non-fat dried milk. ab109526 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated overnight at 4°C at 1 in 1000 and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-TAK1 antibody [EPR5984] (<a href='/en-us/products/primary-antibodies/tak1-antibody-epr5984-ab109526'>ab109526</a>) at 1/1000 dilution

Lane 1:

Wild-type HEK-293T cell lysate at 20 µg

Lane 2:

MAP3K7 knockout HEK-293T cell lysate at 20 µg

Lane 2:

Western blot - Human MAP3K7 (TAK1) knockout HEK-293T cell line (<a href='/en-us/products/cell-lines/human-map3k7-tak1-knockout-hek-293t-cell-line-ab266555'>ab266555</a>)

Predicted band size: 35 kDa,36 kDa,43 kDa,47 kDa,60 kDa,67 kDa,74 kDa

Observed band size: 36 kDa,60 kDa,72 kDa,95 kDa

false

Sanger Sequencing - Human MAP3K7 (TAK1) knockout HEK-293T cell lysate (AB256984)
  • Sanger seq

Unknown

Sanger Sequencing - Human MAP3K7 (TAK1) knockout HEK-293T cell lysate (AB256984)

Homozygous : 2 bp insertion in exon 6

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Knockout validation

Sanger Sequencing,Western blot

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 2 bp insertion in exon 6.

style
left-column

Complementary Products

Primary Antibodies

AB109526

Anti-TAK1 antibody [EPR5984]

RabMAb|Recombinant|KO Validated

Western blot - Anti-TAK1 antibody [EPR5984] (AB109526)

  • 4
  • 2
Proteins & Peptides

AB132950

Recombinant human TAK1 protein

Functional Studies - Recombinant human TAK1 protein (AB132950)

  • 0
  • 0
style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }
style
left-column

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

style
left-column

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab256984-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human MAP3K7 knockout HEK293T cell lysate", "number":"AB256984-CMP01", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HEK293T cell lysate", "number":"AB256984-CMP02", "productcode":"" } ] } } }
style
left-column

Properties and storage information

Gene name
MAP3K7
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Zygosity
Homozygous
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

TAK1 also known as MAP3K7 (Mitogen-activated protein kinase kinase kinase 7) is an important protein kinase that weighs approximately 63 kDa. This protein is expressed in various tissues and cells including HEK 293T cells. TAK1 plays a mechanical role as a part of the MAPK signaling cascade. It phosphorylates and activates downstream kinases which is key to transmitting cellular signals that regulate responses to external stimuli like cytokines and stress.
Biological function summary

TAK1 is involved in several cellular processes necessary for maintaining balance and responding to stress. TAK1 forms a complex with proteins like TAB1 TAB2 and TAB3 which are important for its activation and signaling function. This complex facilitates TAK1's involvement in inflammation and immune response indicating its significance in mediating cellular survival and apoptosis.

Pathways

TAK1 operates within the NF-κB and MAPK pathways two critical routes for cellular response to inflammation and stress. In the NF-κB pathway TAK1 activates IKK which triggers the degradation of IκB freeing NF-κB to move into the nucleus and activate transcription. In the MAPK pathway TAK1 directly influences JNK and p38 cascades revealing regulatory connections to proteins like MEK and ERK.

TAK1 has been linked to conditions such as cancer and inflammatory diseases. In cancers aberrant TAK1 activity can lead to enhanced cell proliferation and survival. Moreover inflammation-related disorders can arise from malfunctioning TAK1 signaling demonstrating its connection to proteins like TNF receptor-associated factors which are involved in inflammatory responses. Understanding TAK1's role in these disorders may pave the way for developing potential therapeutic interventions.
style
left-column

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

style
left-column

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

style
left-column

Product protocols

style
left-column
style
left-column
style
right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com